Lovie Bey, MD
Medical Oncology · Littleton, CONPI 1467414615
Payments from drug & device makers
Across 34 payments — averaging $21.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$125
- Karyopharm Therapeutics Inc.$80
- Gilead$69
- Eisai Inc.$58
- AstraZeneca$53
- Johnson & Johnson$44
- plus $306 from 14 others
What the payments were for
- Food & beverage$63086%
- Education$10514%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 5 | $125 |
| Karyopharm Therapeutics Inc. | 3 | $80 |
| Gilead | 4 | $69 |
| Eisai Inc. | 3 | $58 |
| AstraZeneca | 2 | $53 |
| Johnson & Johnson | 2 | $44 |
| Pfizer | 2 | $37 |
| AbbVie | 1 | $29 |
| Merck | 1 | $28 |
| Array Biopharma Inc | 1 | $24 |
| Myovant Sciences Inc. | 1 | $24 |
| Novartis | 1 | $22 |
| Rigel Pharmaceuticals, Inc. | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $19 |
| ADC Therapeutics America, Inc. | 1 | $18 |
| Grifols USA, LLC | 1 | $16 |
| Caris MPI, Inc. | 1 | $16 |
| Sanofi | 1 | $15 |
| Seagen Inc. | 1 | $15 |
How this compares
$735 in reported general payments places this provider in the 30th percentile of 96 medical oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 11 | $136,481 |
| Abiraterone Acetate | 26 | $3,624 |
| Dexamethasone | 27 | $385 |
| Anastrozole | 24 | $357 |
| Prednisone | 33 | $187 |
| Prochlorperazine Maleate | 16 | $183 |
| Ondansetron Hcl | 11 | $87 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Littleton
- Gerald FalchookDenver$16.1M
- Karl LewisAurora$12.4M
- Christopher LieuAurora$8M
- David CamidgeAurora$7.3M
- Theresa MedinaAurora$7M
- Wells MessersmithAurora$6.3M
- Antonio JimenoAurora$5.6M
- Elizabeth KesslerAurora$5.1M
- Sarah DavisAurora$3.9M
- Sunnie KimAurora$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.